72 results about "Clostridium sp" patented technology

The invention discloses a compound microbial agent for preventing and treating fusarium wilt of cotton and application of the compound microbial agent, and belongs to the technical field of biological prevention and treatment of plant diseases. The prepared compound microbial agent is obtained by mixed culture of clostridium butyricum JBH-BD1 fermentation centrifugate, enterococcus faecium JBHBIO-BSC1, glucose and bacillus subtilis JBH-BK8, the preparation method is simple, and industrialized production, popularization and application are facilitated. The compound microbial agent has an obvious inhibition effect on cotton fusarium wilt caused by fusarium oxysporum, and the bacteriostasis rate reaches 66.7%. The harm of the cotton fusarium wilt to cotton is effectively reduced by utilizing a biotechnology, meanwhile, compared with a chemical agent, the problems of environmental pollution and the like are effectively avoided, and the application prospect is very wide.

The invention discloses application of a lucid ganoderma extract combined with clostridium butyricum in preparation of fat-reducing food or medicine. The invention finds that the ganoderma lucidum extract is combined with clostridium butyricum for use, so that the weight gain of a mouse induced by high-fat diet can be obviously slowed down, the epididymal fat weight of the high-fat mouse is reduced, and the lipid accumulation in the liver and serum of the mouse is reduced; according to the present invention, with the application of the polypeptide, the fat cell size is reduced, the expression of the key gene mRNA related to lipid metabolism and synthesis in the mouse liver is reduced, the intestinal flora of the mouse is regulated, the obesity can be well improved, and the important application prospect in the preparation of the drugs or food for treating diabetes, reducing blood fat, obesity and non-alcoholic fatty liver disease is provided.

The invention discloses a method for improving the fermentation performance of clostridium aerovorans and application of the clostridium aerovorans, and according to the method, an effective amount of methionine or a derivative thereof is added into a fermentation culture medium of the clostridium aerovorans to completely replace expensive complex organic nitrogen sources such as yeast extracts. The method successfully solves the three technical bottlenecks of slow biomass accumulation, low ethanol yield and dependence on expensive nitrogen sources in the fermentation process of the clostridium aerovorans by utilizing synthesis gas or CO2 / H2 mixed gas. Experiments prove that methionine or a derivative thereof can synergistically promote growth metabolism of thalli and a synthesis path of a product, so that the gas conversion efficiency of a carbon source is remarkably improved and metabolism is guided to flow to ethanol synthesis while the growth rate and the final biomass of the thalli are improved, and thus the production capacity of alcohols is synchronously enhanced. The method is simple in process and remarkable in effect, and an efficient and economical new strategy is provided for reducing the production cost of biofuel and promoting industrial application of a synthesis gas biorefinery technology.

The invention belongs to the technical field of microorganisms, and particularly relates to a caproic acid-producing microbial composition and application thereof. According to the specific technical scheme, the microbial composition comprises caproic acid bacteria, clostridium and lactic acid bacteria. The caproic acid producing microbiome provided by the invention not only can be used for resourceful treatment of wastewater with high lactic acid concentration and reduction of environmental protection cost, but also can be used for construction and maintenance of pit mud, and provides a new practical reference for research of Luzhou-flavor liquor synthesis microbiome and preparation of artificial pit mud.

The invention relates to a method for producing higher alcohols. The invention also relates to a reaction mixture and a method for producing at least one higher alcohol, said method comprising a reaction mixture comprising a mixed culture of a first and a second microorganism in an aqueous medium comprising carbon monoxide gas, wherein the first microorganism is an acetogenic microorganism capable of converting a carbon source to acetic acid and / or ethanol; and-the second microorganism is selected from the group consisting of Clostridium kluyveri capable of converting acetic acid and / or ethanol to form an acid, and C. carboxidivorans; wherein the first microorganism is further capable of converting the acid to the corresponding higher alcohol, and the higher alcohol comprises at least 6 carbon atoms.

The invention provides a microbial deodorant and a production process thereof, and relates to the technical field of deodorants. The microbial deodorant is prepared from the following raw materials: 40 to 45 parts of a pyroligneous liquor-ferrous citrate compound, 7 to 10 parts of a lactobacillus plantarum microbial agent, 6 to 8 parts of a lactobacillus acidophilus microbial agent, 3 to 5 parts of a bacillus licheniformis microbial agent, 2 to 3 parts of a clostridium butyricum microbial agent and 19 to 24 parts of carrageenan nano microspheres. The pyroligneous liquor-ferrous citrate compound is prepared by the following steps: adding NaHCO3 into pyroligneous liquor to adjust the pH value to be weakly acidic to obtain pretreated pyroligneous liquor, then adding a ferrous citrate solution into the pretreated pyroligneous liquor, and reacting to obtain the pyroligneous liquor-ferrous citrate compound; the carrageenan nano-microsphere is prepared from the following raw material components: sophora flower polysaccharide, carrageenan, an emulsifier, paraffin and CaCl2. The microbial deodorant disclosed by the invention has excellent deodorization performance and relatively high stability.

The invention relates to application of engineered clostridium butyricum for producing tryptophan in delaying senescence and improving metabolism, and belongs to the technical field of biomedical engineering. The invention discloses an application of engineered clostridium butyricum for expressing tryptophan biosynthetase trpEDCBA in preparation of drugs for delaying senescence, improving metabolism and increasing intestinal beneficial flora. An aging mouse model is constructed, it is found that after the aged mouse orally takes the engineered clostridium butyricum, the muscle strength, the blood glucose homeostasis, the cell metabolism, the cognitive ability and other aspects are remarkably improved, the improvement effect of the engineered clostridium butyricum is better than that of direct taking of butyric acid and tryptophan, the tryptophan-producing clostridium butyricum can be colonized in intestinal tracts for a long time, and the tryptophan-producing effect of the engineered clostridium butyricum is improved. The abundance of effective microbial communities in intestinal tracts is improved, a new tool and means are provided for anti-aging, and good application prospects are achieved.

The invention belongs to the technical field of microorganisms, and discloses clostridium butyricum ML5358 and application thereof.The clostridium butyricum ML5358 provided by the invention has the preservation number of CGMCC No.37000. The strain can effectively relieve mouse colitis induced by DSS and remarkably reduce expression of colon tissue inflammatory factors Il-6 and Il-1beta, and the preservation number of the clostridium butyricum ML5358 is CGMCC No.37000. The clostridium butyricum ML5358 is CGMCC No.37000. The clostridium butyricum ML5358 is CGMCC No.37000. In addition, skeletal muscle lipid metabolism can be regulated and controlled through the intestine-muscle axis, expression of fat synthesis and uptake related genes Srebf1, Acc1 and Fabp4 is specifically up-regulated, the content of intramuscular triglyceride is remarkably increased, and intramuscular fat deposition is promoted. According to the clostridium butyricum ML5358 and the application thereof, the functional limitation of traditional clostridium butyricum is broken through, and a new strain resource is provided for developing a novel microbial preparation or a feed additive capable of improving intestinal health and improving livestock and poultry meat quality.

The invention relates to the field of biological medicines, relates to a treatment technology for early abortion, and in particular relates to an application of Clostridium prausnitzii (Faecalibacterium prausnitzii) in preparation of a medicine for treating early abortion. An experiment of a Poly (I: C) induced early-stage abortion mouse model proves that the clostridium praeparatum can obviously reduce the embryo loss rate and improve placenta development through oral intragastric administration. The action mechanism is that maternal immune balance is regulated by increasing the proportion of regulatory T cells (Treg) and inhibiting excessive activation of an IL-17 signal channel. As human intestinal symbiotic bacteria, the clostridium praeparatum is high in safety and can be used for intervention of early abortion, especially recurrent abortion, and a new strategy is provided for clinic.

The invention discloses application of clostridium butyricum based on clostridium butyricum with the product number of BNCC337239 in preparation of a medicine or food for treating and / or preventing polycystic ovarian syndrome, and a culture method of the clostridium butyricum based on clostridium butyricum based on clostridium butyricum based on clostridium butyricum based on clostridium butyricum based on clostridium butyricum based on clostridium butyricum. According to the present invention, the bacterial strain is subjected to anaerobic culture to prepare the bacterial liquid, the intragastric administration frequency is 1-3 times per week at the dosage of 0.1-0.5 mL / 100 g, and the intragastric administration lasts for 3-8 weeks, such that the estrus cycle disorder, the insulin resistance, the blood sex hormone disorder and the ovarian polycystic degeneration of the PCOS rat model can be significantly improved, and the method can be used for preparing the drug for treating the polycystic ovarian syndrome.

The invention discloses a clostridium aerovorans continuous fermentation method based on multi-parameter regulation and control, and belongs to the technical field of microbial fermentation. The method comprises the following parameter control: fermentation culture medium concentration control: in a biomass stabilization stage, gradually reducing the fermentation culture medium concentration from an initial concentration so as to reduce an acid production ratio and improve an alcohol production ratio; the CO content in the tail gas is controlled, wherein the volume fraction of CO in the tail gas is controlled to be 5-10%, and therefore the growth rate of the clostridium aerovorans is increased; dilution degree control: gradually improving the dilution degree so as to improve the fermentation yield; wherein the dilution is equal to the product of the fermentation culture medium feeding speed and 24 / fermentation liquid volume; a ceramic membrane is added, and thalli are intercepted by adding the ceramic membrane, so that the biomass is improved. According to the method, the fermentation acid-alcohol ratio can be regulated and controlled, and the fermentation rate of the clostridium aerovorans is increased.

The present disclosure relates to methods of producing a 900 kDa BoNT / A complex, wherein the method does not comprise a step of precipitation during the purification process. Further provided herein are methods of preparing a Clostridium botulinum working cell bank (WCB).

Present invention relates to a method of treating a disorder by administering an effective amount of a pharmaceutical composition comprising a therapeutic agent bound to a p80 neurotoxin associated polypeptide (NAP) derived from Clostridium Botulinum Type E (BoNT / E). The p80 is bound to a therapeutic agent, comprising one or more of: drugs, dyes, small molecules, biomolecules, proteins or a combination thereof. P80 enhances the transportation of the therapeutic agent into the bloodstream for increased bioavailability because thep80 is a tight junction modulator to enhance the permeability of the intestinal epithelium so as to facilitate drug delivery.

The invention relates to the technical field of animal husbandry, in particular to a multipurpose animal feed conditioner and a using method thereof, and the conditioner is prepared from the following components in percentage by weight: 0.05%-0.1% of bacillus, 0.05%-0.1% of clostridium butyricum, 0.1%-0.2% of saccharomycetes, 0.05%-0.1% of lactobacillus acidophilus, 2.0% of glucose, 0.15% of yeast extract, 0.1%-0.15% of dipotassium phosphate, 0.05% of magnesium sulfate, 0.1% of sodium chloride and the balance of water. Through the synergistic effect of multiple bacteria, the feed utilization rate is remarkably increased, the animal growth is promoted, the immunity is enhanced, the use of antibiotics is reduced, the environmental pollution is reduced, and the synergistic development of economic benefits, ecological benefits and social benefits of livestock and poultry breeding is realized.

The present disclosure provides use of Clostridium ghonii combined with a tumor angiogenesis inhibitor in preparing a pharmaceutical product for treating a tumor. The present disclosure further provides a drug for treating a tumor, where the drug includes active ingredients of Clostridium ghonii and a tumor angiogenesis inhibitor.

The invention discloses a feed additive for improving growth performance of growing-finishing pigs, improving meat quality and reducing odor emission, and is characterized in that the feed additive is composed of the following components in parts by weight: 10-20 parts of an anise leaf extract and 75-90 parts of a probiotic composition; the probiotic composition is prepared from the following bacteria: 1.5 * 10 < 13 > to 4.5 * 10 < 13 > CFU / kg of bacillus subtilis, 1.5 * 10 < 13 > to 4.5 * 10 < 13 > CFU / kg of bacillus coagulans, 4 * 10 < 12 > to 6 * 10 < 12 > CFU / kg of clostridium butyricum and 5 * 10 < 12 > to 7 * 10 < 12 > CFU / kg of bacillus licheniformis.

This invention relates to the field of microbial technology, specifically to a method for the production and extraction of N-acetylmuroic acid-L-alanine amidase via microbial fermentation. The method for preparing N-acetylmuroic acid-L-alanine amidase provided by this invention utilizes *Clostridium beijerinckii* XH0906 for fermentation to produce N-acetylmuroic acid-L-alanine amidase. As the main extracellular protein of this bacterium, N-acetylmuroic acid-L-alanine amidase has a high yield and is beneficial for subsequent separation and purification. This method has advantages such as simplicity, efficiency, and low cost, providing an effective method for the preparation of N-acetylmuroic acid-L-alanine amidase, and has good application prospects in the fields of microbial food, biomedicine, and antibacterial applications.

The present invention discloses a variant D-allulose 3-epimerase (DAEase) that is distinguished from a wild-type DAEase derived from Spirochaetales bacterium (spDAEase) by at least one amino acid sequence variation comprising substitution of an 5 amino acid residue corresponding to position 69, 119, 138, 175, 203, 208, 229, 240, or 265 of SEQ ID NO. 1; or a variant DAEase that is distinguished from a wild-type DAEase derived from Clostridium cellulolyticum (ccDAEase) by an amino acid sequence variation comprising substitution of an amino acid at position 46 and / or a truncation of C-terminal end of in SEQ ID NO. 2.

The invention discloses an intestinal flora marker related to metabolic heterogeneity of azathiopurine (AZA) and application of the intestinal flora marker, and belongs to the technical field of personalized drug treatment of inflammatory bowel diseases (IBD). In particular, the invention finds that a specific intestinal flora marker is significantly related to the level of an AZA active metabolite 6-thiopurine nucleotide (6-TGN). For example, the prevotella abundance can be used for distinguishing IBD patients with different 6-TGN exposure levels, has an indication effect on the in-vivo 6-TGN concentration, and has an important application value in thiazopurine therapeutic drug monitoring (TDM). In addition, clostridium species Clostridium sp.OF09-36 and Clostridium sp.AF32-12BH are significantly enriched in a 6-TGN high-exposure patient group, and the microbiome of the clostridium sp.OF09-36 and Clostridium sp.AF32-12BH encodes enzyme genes participating in purine metabolism, such as GMPS, HPRT, IMPDH and the like, which indicate that the Clostridium sp.OF09-36 and Clostridium sp.AF32-12BH are potential intestinal flora targets for regulating and controlling AZA metabolism. The intestinal flora marker provided by the invention provides a new biomarker and an intervention target for optimization and adjustment of AZA therapeutic dose and individualized precise treatment of IBD.

According to the present invention, provided is a Clostridium perfringens sporulation inhibitor that contains at least one inorganic compound at such a concentration as to cause the precipitation of C. perfringens in vivo, wherein the inorganic compound is a salt of at least one selected from the group consisting of K, Na, Mg, Ca and Fe and the inorganic compound is coated with a protective layer containing a hardened vegetable oil.

This invention belongs to the field of microbial technology, and relates to a *Pediococcus pentosacchari* strain derived from geese, its isolation and screening method, and its application. The *Pediococcus pentosacchari* strain is *Pediococcus pentosacchari*. Pediococcus pentosaceus L2, deposited at the Guangdong Provincial Microbial Culture Collection Center, accession number GDMCC No:67207. This invention, *Pediococcus pentosaceus* L2, was isolated and screened from the cecum of healthy Magang geese. Its source is reliable and readily available, possessing safety and probiotic properties. It exhibits good antibacterial activity against *Clostridium perfringens*, demonstrating excellent probiotic potential for application in feed additives, probiotic preparations, and medications for treating geese infected with *Clostridium perfringens*.

The present invention relates to a method of purifying a non-toxic protein-removed Clostridium botulinum neurotoxin protein.

Provided herein, inter alia, are methods and compositions for the treatment of cancer. The compositions include one or more anti-cancer agents and Clostridium butyricum. Administration of Clostridium butyricum can enhance the therapeutic effects of anti-cancer agents, thereby increasing the efficacy of said agents for cancer treatment.

Methods and compositions for treating cancer are provided.SOLUTION: The compositions comprise one or more anti-cancer agents and Clostridium butyricum. Administration of Clostridium butyricum can increase the therapeutic effect of the anti-cancer agent, thereby increasing the effectiveness of said agent for treating cancer.SELECTED DRAWING: Figure 5

The present invention relates to a culture medium composition for producing botulinum toxin, and more particularly to a culture medium composition for culturing Clostridium sp. strains capable of producing botulinum toxin. When a Clostridium botulinum strain is cultured using a culture medium comprising vegetable peptone, glucose, and yeast extract without animal-derived components, the growth rate of the strain is increased compared to existing culture media, and the strain can be safely cultured since animal-derived components are not included, thereby increasing the yield of botulinum toxin.

Avian necrotic enteritis (NE) is a complex and multifactorial enteric disease of commercial chickens and turkeys that has major economic consequences on the poultry industry worldwide. There is thus a need for improved and efficient vaccines for the prevention of diseases associated to pathogenic Clostridium perfringens in the poultry industry. The present application discloses immunogenic polypeptides unique to pathogenic strains of Clostridium perfringens which causes avian NE, as well as vaccine compositions comprising one or more of the immunogenic polypeptides, immunogenic fragments thereof, or nucleic acids encoding such immunogenic polypeptides and fragments. Methods and uses of the vaccine compositions for inducing or eliciting an immune response against Clostridium perfringens, for preventing or treating infection by Clostridium perfringens, and / or for preventing or treating avian NE in an animal, such as a poultry, are also disclosed.

The invention discloses a composite single-cell protein feed for improving anti-infection immunity of micropterus salmoides and application of the composite single-cell protein feed, and belongs to the technical field of feed preparation. The feed comprises composite single-cell protein for replacing 40-100% of fish meal, and the composite single-cell protein comprises chlorella and clostridium ethanol protein in a mass ratio of 1: (4-5). The compound single-cell protein is adopted to replace part of fish meal in the feed, so that the cost of the feed can be remarkably reduced, the anti-infection immunity of the micropterus salmoides to aeromonas hydrophila can be improved, expression down-regulation of a pro-apoptosis gene casp8 and an antigen presentation related gene mhci in the micropterus salmoides can be promoted, and the apoptosis resistance of the micropterus salmoides can be improved. The expression up-regulation of the anti-apoptosis gene bcl2l1 and the anti-ferroptosis gene gpx4a is promoted. In addition, the liver metabolism function of the micropterus salmoides can be improved, and lipid metabolism is promoted.

Shelf-stable packaged low acid-beverages and methods for the same are disclosed. The shelf-stable packaged low acid beverage may include a container and a liquid low acid beverage disposed and sealed in the container. The liquid low acid beverage may include oxygen dissolved therein in an amount sufficient to prevent growth of bacteria, such as Clostridium botulinum or other bacteria such as Psychotrophs or lactic bacteria. The method may include dissolving the liquid low acid beverage into the container, dissolving oxygen and / or nitrogen into the low liquid beverage disposed in the container, and sealing the container. The container and the liquid low acid beverage may define a headspace disposed in the container. The oxygen may be present in the headspace in an amount greater than 0%, or greater than or equal to about 12%, based on the volume of the headspace.